Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Dermatologic 1CNS 1Breast 1

Conditions

Melanoma 2Triple Negative Breast Neoplasms 1Sarcoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Lung Neoplasms 1Hematologic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 3trametinib 2pertuzumab 2dabrafenib 2Trastuzumab 2Tacrolimus 2Specimen Handling 2Polymerase Chain Reaction 2Nivolumab 2Biopsy 2ulixertinib 1trastuzumab biosimilar HLX02 1tinostamustine 1temsirolimus 1sonidegib 1selinexor 1sapanisertib 1romidepsin 1relatlimab 1palbociclib 1osimertinib 1omipalisib 1merphos 1larotrectinib 1ipatasertib 1fludarabine phosphate 1erdafitinib 1entrectinib 1defactinib 1copanlisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × bintrafusp alfa protein, human × Dermatologic × Clear all
NCT04789668 2026-03-18

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

M.D. Anderson Cancer Center

Phase 1/2 Terminated
8 enrolled 13 charts
BreastCNSDermatologicOther hematologic neoplasmThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡